Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Standard BioTools Inc. (LAB)

2.13   0.14 (7.04%) 01-27 16:00
Open: 1.98 Pre. Close: 1.99
High: 2.13 Low: 1.97
Volume: 191,219 Market Cap: 169(M)

Technical analysis

as of: 2023-01-27 4:45:56 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 2.48     One year: 2.9
Support: Support1: 1.49    Support2: 1.1
Resistance: Resistance1: 2.13    Resistance2: 2.48
Pivot: 1.92
Moving Average: MA(5): 2.03     MA(20): 1.77
MA(100): 1.35     MA(250): 2.04
MACD: MACD(12,26): 0.1     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 92.3     %D(3): 91.7
RSI: RSI(14): 74.7
52-week: High: 4.23  Low: 0.92
Average Vol(K): 3-Month: 268 (K)  10-Days: 222 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ LAB ] has closed below upper band by 16.9%. Bollinger Bands are 33.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.13 - 2.14 2.14 - 2.16
Low: 1.94 - 1.96 1.96 - 1.97
Close: 2.11 - 2.13 2.13 - 2.15

Company Description

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Headline News

Sun, 29 Jan 2023
I drove 10 hours to watch a 9-minute Rocket Lab launch from Virginia and it was glorious -

Sat, 28 Jan 2023
IAN BIRRELL: UN experts say lab leak was the 'most likely' cause of Covid-19 - Daily Mail

Sat, 28 Jan 2023
How a UP laboratory is developing safer food packaging -

Sat, 28 Jan 2023
Fayetteville is getting a 'smash room' - 4029tv

Sat, 28 Jan 2023
Tyler Perry concerned about emissions from future FDA lab near his studio - The Atlanta Journal Constitution

Fri, 27 Jan 2023
Is lab-grown steak kosher? Religious leaders weigh the sensitive question - The Washington Post

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 0 (M)
Shares Float 48 (M)
% Held by Insiders 2 (%)
% Held by Institutions 78.9 (%)
Shares Short 3,620 (K)
Shares Short P.Month 3,820 (K)

Stock Financials

EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) -145.6
Operating Margin (%) -83.4
Return on Assets (ttm) -16
Return on Equity (ttm) -85.2
Qtrly Rev. Growth -39.5
Gross Profit (p.s.) 0.39
Sales Per Share 1.42
EBITDA (p.s.) -0.99
Qtrly Earnings Growth 0
Operating Cash Flow -62 (M)
Levered Free Cash Flow -33 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 1.49
Price to Cash Flow -0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.